Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
3.
Eur J Clin Microbiol Infect Dis ; 19(2): 96-100, 2000 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-10746494

RESUMO

The role of gastric acid inhibitors as predisposing factors for Candida esophagitis is unknown. A retrospective case-control study of esophageal candidiasis was conducted in human immunodeficiency virus (HIV)-negative patients diagnosed from January 1991 to December 1997. The diagnosis of esophageal candidiasis was always made on the basis of endoscopic and histological criteria. Fifty-one patients were diagnosed with esophageal candidiasis, 15 of whom had esophageal complaints and 48 of whom suffered from another previous chronic disease (17 had cancer). In addition, 20 patients had previously been treated with antibiotics, 13 with steroids and 14 with omeprazole. In the multivariate analysis, neoplasm (odds ratio, 5.50; 95% confidence interval, 1.94-15.56) and therapy with antibiotics (odds ratio, 11.97; 95% confidence interval, 3.82-37.45), steroids (odds ratio, 35.52; 95% confidence interval, 3.90-324.01) or omeprazole (odds ratio, 18.23; 95% confidence interval, 4.67-71.03) were all associated with esophageal candidiasis. These data suggest that Candida esophagitis tends to occur in patients with chronic diseases, most of whom have been previously treated with antibiotics, steroids or omeprazole. The findings support the hypothesis that treatment with omeprazole favors the development of esophageal candidiasis.


Assuntos
Candidíase/etiologia , Esofagite/microbiologia , Idoso , Idoso de 80 Anos ou mais , Antibacterianos/uso terapêutico , Antiulcerosos/uso terapêutico , Candidíase/diagnóstico , Candidíase/patologia , Estudos de Casos e Controles , Doença Crônica , Esofagite/diagnóstico , Esofagite/patologia , Esofagoscopia , Feminino , Soronegatividade para HIV , Humanos , Masculino , Pessoa de Meia-Idade , Análise Multivariada , Omeprazol/uso terapêutico , Estudos Retrospectivos , Fatores de Risco , Esteroides/uso terapêutico
5.
An Otorrinolaringol Ibero Am ; 25(1): 45-56, 1998.
Artigo em Espanhol | MEDLINE | ID: mdl-9542247

RESUMO

The rhinocerebral mucormycosis is the more common form produced by Rhizopus, a genus of fungi. It's a serious infective disease with high mortality, that needs a precocious medical treatment. Amphotericin B is the choice medical treatment, but liposomal amphotericine B in recent years is a better drug, due to minor renal toxicity and greater tisular diffusion. Even can not to treat all affected areas it's necessary an extensive surgical treatment according to individual characteristics and disease evolution. A 56-year-old man with rhinocerebral mucormycosis, caused by Rhizopus, who was treated with liposomal-amphotericin B and extensive rhino-orbital surgery is presented.


Assuntos
Anfotericina B/uso terapêutico , Antifúngicos/uso terapêutico , Córtex Cerebral/cirurgia , Mucormicose/terapia , Seios Paranasais/cirurgia , Encefalopatias/diagnóstico por imagem , Encefalopatias/microbiologia , Encefalopatias/cirurgia , Córtex Cerebral/diagnóstico por imagem , Córtex Cerebral/microbiologia , Humanos , Masculino , Pessoa de Meia-Idade , Mucormicose/diagnóstico por imagem , Mucormicose/microbiologia , Doenças dos Seios Paranasais/diagnóstico por imagem , Doenças dos Seios Paranasais/microbiologia , Doenças dos Seios Paranasais/cirurgia , Seios Paranasais/diagnóstico por imagem , Seios Paranasais/microbiologia , Rhizopus/isolamento & purificação , Tomografia Computadorizada por Raios X
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA